<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83252">
  <stage>Registered</stage>
  <submitdate>8/10/2008</submitdate>
  <approvaldate>6/01/2009</approvaldate>
  <actrnumber>ACTRN12609000003279</actrnumber>
  <trial_identification>
    <studytitle>Cisplatin and oral vinorelbine chemotherapy along with radiation for treatment of locally advanced lung cancer</studytitle>
    <scientifictitle>A phase II trial evaluating progression free survival with cisplatin and oral vinorelbine plus radiation for Stage III Non Small Cell Lung Cancer</scientifictitle>
    <utrn />
    <trialacronym>CoVERT</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Stage III Non Small Cell Lung Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Oral vinorelbine 50 mg/m2 day 1,8 along with intravenous cisplatin at dose of 50 mg/m2 day 1,8 every 3 weeks for 2 cycles along with 60 Gy radiation treatment at the rate of 2 Gy per fraction. All the treatment is given simultaneously.</interventions>
    <comparator>None</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression free survival using computerised tomography (CT) scan</outcome>
      <timepoint>2 monthly follow up till evidence of disease progression or death.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>response rate using CT scan</outcome>
      <timepoint>4 weeks after completion of treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Histologically or cytologically (fine needle aspiration) proven non-small cell lung cancer
Performance status 0-1
Forced expiratory volume (FEV1) &gt;1 Ltr
Adequate hematology and biochemistry</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Neuropathy &gt; Grade 1
Uncontrolled medical disorder
Malabsorption syndrome
Women if pregnant or breast-feeding</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/08/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Royal Adelaide Hospital</primarysponsorname>
    <primarysponsoraddress>North Terrace
Adelaide, SA 5000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Pierre Fabre Medicament Pvt Ltd</fundingname>
      <fundingaddress>26B/1 Maitland Pl
Baulkham Hills
NSW, 2153</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study is looking at efficacy of combination of oral vinorelbine and cisplatin with radiation for locally advanced lung cancer. The combination is unique as it combine oral with intravenous treatment.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Nimit Singhal</name>
      <address>Cancer Centre, Royal Adelaide Hospital, North Terrace
Adelaide, SA 5000</address>
      <phone>+61 8 88224398</phone>
      <fax />
      <email>nimit.singhal@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Nimit Singhal</name>
      <address>Cancer Centre, Royal Adelaide Hospital, North Terrace, Adelaide, SA 5000</address>
      <phone>+61 8 8224398</phone>
      <fax />
      <email>nimit.singhal@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>